Login to Your Account



NewCo News

Start-up Ra Pharma Emerges from Stealth, Targeting HAE

By Marie Powers
Staff Writer

Thursday, May 17, 2012
Four years after its launch and two years after the company quietly secured a $27 million Series A round, Ra Pharmaceuticals Inc. revealed hereditary angioedema (HAE) as the initial target for its cyclomimetics – peptide-like molecules that incorporate non-natural amino acids.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription